Auditory perception

Neosensory partners with Oaktree Products to distribute new tinnitus program, Neosensory Duo, to US audiologists

Retrieved on: 
Tuesday, July 13, 2021

Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.

Key Points: 
  • Neosensory has been developing innovative hearing and sensory augmentation solutions since 2015 and was recently recognized by Fast Company's 2021 World Changing Ideas Awards.
  • This proprietary, non-invasive method known as bimodal stimulation leverages neuroplasticity and has been shown to reduce tinnitus symptoms in more than 87% of users.
  • For more information about Neosensory and its products, contact Neosensory at [email protected] or visit https://neosensory.com .
  • The company's tinnitus program, Neosensory Duo, launched in March 2021, is based on new scientific research on bimodal stimulation.

Neuromod research reveals that more than three in four UK tinnitus sufferers have never received treatment for their condition

Retrieved on: 
Tuesday, July 13, 2021

The poll also revealed that 67% of UK tinnitus sufferers don't feel adequately informed about their condition.

Key Points: 
  • The poll also revealed that 67% of UK tinnitus sufferers don't feel adequately informed about their condition.
  • The research, which polled 251 people with tinnitus across the UK, found that 76.1% of respondents have never used any form of tinnitus treatment.
  • This may stem from the fact that so many people with tinnitus never seek any form of treatment for it.
  • The Lenire tinnitus treatment device is available to people with tinnitus through The Tinnitus Clinic's network of seven locations across the UK or online via the company's Neuromod Medical tinnitus telemedicine service.

Onset Financial Funds $40M for an International Energy Provider

Retrieved on: 
Friday, June 25, 2021

Leveraging their strong funding relationships, Onset Financial funded $40M for an energy provider.

Key Points: 
  • Leveraging their strong funding relationships, Onset Financial funded $40M for an energy provider.
  • This lease transaction enabled the energy provider to begin implementing its growth strategies.
  • Onset was able to present the customer with a creative structure that highlighted the flexibility that Onset is uniquely suited to offer.
  • As an energy provider, Onsets customer serves vital power needs throughout the nation and internationally.

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Retrieved on: 
Friday, May 14, 2021

They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.

Key Points: 
  • They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks.
  • \xe2\x80\x9cWe look forward to completing the TRAVERS trial later in 2021 and to advancing the AM-125 program further.
  • There is a strong medical need for a novel drug in this area, with e.g.
  • In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi\xc2\xae (AM-111) for acute inner ear hearing loss and Keyzilen\xc2\xae (AM-101) for acute inner ear tinnitus.

Global Tinnitus Pipeline Insight Report 2021: Focus on Key Players, Major Products and Research Programmes - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021

b'The "Tinnitus - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Tinnitus Pipeline Insight, 2021 report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in Tinnitus pipeline landscape.

Key Points: 
  • b'The "Tinnitus - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Tinnitus Pipeline Insight, 2021 report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in Tinnitus pipeline landscape.
  • It covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThe companies and academics are working to assess challenges and seek opportunities that could influence Tinnitus R&D.
  • Phase III include, Auris Medical.\nTinnitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.\n'

Neosensory Wins Honorable Mention in Health and Wellness in Fast Company's 2021 World Changing Ideas Awards

Retrieved on: 
Wednesday, May 5, 2021

Customers use it for reasons including hearing loss, music enjoyment, entertainment, and the addition of new senses.

Key Points: 
  • Customers use it for reasons including hearing loss, music enjoyment, entertainment, and the addition of new senses.
  • The company recently launched a breakthrough application of its hardware that helps people suffering from tinnitus (ringing in the ears) through bimodal stimulation (combining sound and touch).
  • "\nFounded in 2015 by neuroscientists David Eagleman and Scott Novich, Neosensory builds non-invasive brain-machine interfaces to create new senses.\nDr.
  • For more information on Neosensory\'s technology and its applications, visit neosensory.com.\nWorld Changing Ideas is one of Fast Company\'s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better.\n'

Five Tips to Manage Tinnitus and Inner Ear Ringing Symptoms

Retrieved on: 
Monday, April 26, 2021

b'CHATTANOOGA, Tenn., April 26, 2021 /PRNewswire/ -- Tinnitus is a medical condition marked by incessant inner ear ringing and similar sounds, impacting more than 50 million Americans .

Key Points: 
  • b'CHATTANOOGA, Tenn., April 26, 2021 /PRNewswire/ -- Tinnitus is a medical condition marked by incessant inner ear ringing and similar sounds, impacting more than 50 million Americans .
  • and Lipo-Flavonoid Chief Audiologist, has seen more cases of tinnitus emerge in the past year, resulting from the COVID-19 pandemic.
  • "Increased ear ringing and hearing loss is often more prevalent during the winter months as there\'s a greater likelihood for flu-related congestion and sinus infections," says Borgia.
  • If you\'re newly experiencing tinnitus, Dr. Borgia has compiled the following tips to help manage symptoms and protect your hearing:\nModify your medications.

 Olive Union Raises $20M to Expand into Digital Hearing Therapeutics

Retrieved on: 
Monday, April 5, 2021

Olive Union - the company making smarter hearing health a reality for everyone - today announced the closing of a $7M Series B.

Key Points: 
  • Olive Union - the company making smarter hearing health a reality for everyone - today announced the closing of a $7M Series B.
  • With the current round and cumulative $20M in lifetime funding, Olive plans to expand beyond its existing hearing aids product line into new digital therapeutics for tinnitus and overall hearing health, and begin laying the foundation for its next generation of smart hearing technology.
  • Collective exposure to prolonged and nearby loud noises has put us in the middle of an unprecedented decline in global hearing health, said Olive Union Founder and CEO, Owen Song.
  • Olive Union blends cutting-edge technology, modern design, and an intuitive user experience to offer affordable hearing for all.

Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

Retrieved on: 
Thursday, March 25, 2021

The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 140 patients with persistent, early onset tinnitus of at least moderate severity.

Key Points: 
  • The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 140 patients with persistent, early onset tinnitus of at least moderate severity.
  • The Phase 2 trial will be conducted at approximately 50 clinical sites in the U.S. and Europe.
  • In 2020, we reported positive results from a Phase 1/2 trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity.
  • This trial demonstrated a positive clinical response for OTO-313 using the Tinnitus Functional Index (TFI) that was correlated with improvements in tinnitus loudness, tinnitus annoyance and patient global impression of change measures.

Eargo Finds the Sounds Americans Miss Most During the Pandemic

Retrieved on: 
Tuesday, March 2, 2021

On World Hearing Day we want to shine a light on hearing and hearing loss, said Eargo CEO Christian Gormsen.

Key Points: 
  • On World Hearing Day we want to shine a light on hearing and hearing loss, said Eargo CEO Christian Gormsen.
  • Like everyone else, were optimistic that the return to normal is right around the corner and we dont want anyone to miss hearing it.
  • Yet not all sonic nostalgia has been tied to sounds of recreation activities that have become less frequent as a result of the pandemic.
  • Seven percent of respondents even miss the sounds of keyboards, phones ringing or a printer printing at their office.